SCHEMBL23999971

SCHEMBL23999971

CC(=O)Nc1ccc(-c2nc3nc(Nc4ccncc4)ccc3[nH]2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
HPGD P15428 5/20 0.55
KDM4E B2RXH2 4/20 0.55
GAA P10253 1/20 0.55
HSD17B10 Q99714 4/20 0.49
TP53 P04637 3/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TDP1 Q9NUW8 1/20 0.48
HPSE Q9Y251 3/20 0.48
DHODH Q02127 2/20 0.46
PARP1 P09874 1/20 0.46
PRMT5 O14744 2/20 0.44
MAPT P10636 1/20 0.43
BRAF P15056 1/20 0.43
ALOX5 P09917 1/20 0.42
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25494178 0.81 RAD52 (0.45) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL23999972 0.78 KDM4E (0.60) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL16498994 0.76 ALDH1A1 (0.73) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL6258154 0.76 HPSE (0.81) ALDH1A1HPGDKDM4EHSD17B10TP53
SCHEMBL6262533 0.73 HPSE (0.81) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL23999988 0.72 ALDH1A1 (0.57) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL20982455 0.70 ALDH1A1 (0.67) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL6466096 0.70 RAF1 (0.68) ALDH1A1HPGDKDM4EGAAKMT2A
SCHEMBL11310448 0.69 ROCK2 (0.55) ALDH1A1HPGDKDM4EGAARAB9A
SCHEMBL3728246 0.69 SMN1; SMN2 (0.76) ALDH1A1HPGDKDM4EGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 WO disclosed
WO-2021226517-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR ALDH1A1 4544/4885HPGD 2437/4885KDM4E 3961/4885
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR ALDH1A1 4541/4885HPGD 2503/4885KDM4E 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.